ArticleJournal of animal science and technology2025
A refined comparative mouse model of acute and chronic atopic dermatitis.
Article in Journal of animal science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The potential effects, mechanisms and translational perspectives of natural products in the treatment of atopic dermatitis.Chinese medicine · 2026Review
- Functional evaluation of synbiotic combination ofCurrent research in food science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine and human atopic dermatitis (AD) is a complex inflammatory skin disorder with an increasing incidence, characterized by distinct acute and chronic phases with unique histological and immunological profiles. Although research into effective treatment methods has been insufficient, there has been a surge in the exploration of probiotics as a therapeutic strategy for AD. Such probiotics are often originated from the animals, and these are being developed to modulate the immune system and enhance skin barrier function, offering promising new treatment options for AD. To better understand the pathogenesis of both canine and human AD and develop treatments, animal models that accurately replicate the symptoms of both species are indispensable. This study aimed to establish a standardized and cost-effective BALB/c mouse model to more accurately simulate canine and human AD using dinitrochlorobenzene (DNCB) alone and in combination with ovalbumin (OVA). We evaluated histological and immunological changes from acute to chronic stages of AD in the mouse model induced by treatment of DNCB alone and DNCB combined with OVA to determine their similarity to both canine and human AD symptoms. The results showed that the pathological changes observed in the mouse AD model demonstrated significant parallels with both species, including increased mast cell infiltration, epidermal thickening, and elevated cytokine levels such as interleukin-4 and interferon-γ. Acute phase observations highlighted pronounced epidermal defects such as dryness and skin erosion, while chronic phase findings indicated persistent skin thickening, inflammation, and notable edema. Although both mouse models showed comparable symptoms and immunological responses, the model induced by the combination of DNCB and OVA more accurately represented canine and human AD compared to the model induced by DNCB alone. This combined DNCB and OVA mouse model provides valuable insights into AD pathogenesis and potential therapeutic targets, underscoring its significance in AD research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.